Retatrutide Half-Life and Pharmacokinetics: What Studies Report

Retatrutide, developed as LY3437943, is an investigational single-molecule agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. Most public interest in its pharmacokinetics comes down to one question: how long does the molecule persist after a dose, and what did the published work actually measure? This page summarises the half-life, route, dosing interval and exposure information that appears in peer-reviewed reports, and — just as importantly — flags the pharmacokinetic parameters that the published abstracts do not describe. This page is for educational purposes only and is not medical advice; consult a licensed physician for questions about any medication or health condition.

Half-Life: What Researchers Reported

The primary pharmacokinetic source in the peer-reviewed literature is the discovery-to-clinical-proof-of-concept report, which described the design of LY3437943 as a fatty-acid-modified synthetic peptide and its first evaluation in humans; researchers reported a half-life of approximately six days, a profile they described as supporting once-weekly subcutaneous administration (https://pubmed.ncbi.nlm.nih.gov/35985340/). That single figure is the anchor for every subsequent trial design: because the reported half-life was on the order of days rather than hours, investigators built weekly injection schedules rather than daily ones.

Narrative reviews of the compound have repeated this characterisation, describing retatrutide as a long-acting, once-weekly agent whose molecular design prolongs circulating exposure relative to unmodified gut hormones (https://pubmed.ncbi.nlm.nih.gov/40563436/). A second review covering the pharmacology of triple agonism similarly framed retatrutide as a weekly-dosed peptide combining GIP, GLP-1 and glucagon receptor activity in one molecule (https://pubmed.ncbi.nlm.nih.gov/39515565/). Neither review, at abstract level, adds independent human pharmacokinetic measurements beyond what the original trial programme reported.

As a general pharmacology principle, a compound given at an interval shorter than several half-lives accumulates until concentrations plateau. The published trials are consistent with this: they administered fixed weekly doses over many weeks and escalated in steps, rather than adjusting exposure day to day.

Route of Administration in the Published Trials

Across the verified literature, one route dominates. The phase 1b multiple-ascending-dose trial in people with type 2 diabetes administered LY3437943 subcutaneously once weekly for 12 weeks (https://pubmed.ncbi.nlm.nih.gov/36354040/). The phase 2 obesity trial used once-weekly subcutaneous retatrutide at 1 mg, 4 mg, 8 mg and 12 mg over 48 weeks (https://pubmed.ncbi.nlm.nih.gov/37366315/). The phase 2 trial in type 2 diabetes also used weekly subcutaneous injection, with doses up to 12 mg and dulaglutide 1.5 mg as an active comparator over 36 weeks (https://pubmed.ncbi.nlm.nih.gov/37385280/). A systematic review and meta-analysis of the randomised evidence was explicitly framed around once-weekly subcutaneous retatrutide (https://pubmed.ncbi.nlm.nih.gov/39318607/).

No oral, intranasal, intravenous or transdermal human administration of retatrutide appears in the verified papers. Any statement about bioavailability by a non-subcutaneous route would therefore have no published basis in this evidence set.

Dose, Interval and Duration As Studied

Absorption: What Is and Is Not Described

The published abstracts confirm subcutaneous absorption sufficient to sustain weekly exposure, but they do not, at abstract level, report the time to maximum concentration (T_max), absolute bioavailability, injection-site dependence, or the shape of the concentration-time curve. The pharmacokinetic characterisation that is reported is essentially summary-level: a half-life of roughly six days in humans and a profile the researchers judged compatible with weekly administration (https://pubmed.ncbi.nlm.nih.gov/35985340/). Readers looking for a full ADME package — absorption rate constants, plasma protein binding fractions, metabolite identification — will not find it in the verified papers summarised here.

Distribution, Metabolism and Clearance: Data Gaps

No human mass-balance study, radiolabelled excretion study, volume-of-distribution estimate or metabolite profile for retatrutide appears in the verified literature. The same applies to formal pharmacokinetic studies in renal impairment, hepatic impairment, or by age, sex and body weight, and to dedicated drug-drug interaction studies. This is a genuine absence in the publicly summarised record rather than an oversight of this page: the trials that exist were designed around efficacy and safety endpoints, with pharmacokinetics reported only to the extent needed to justify the weekly interval.

For fatty-acid-modified peptides as a class, extended duration is generally attributed to reversible albumin binding and reduced renal filtration, and the discovery report described retatrutide as an engineered peptide built for prolonged action (https://pubmed.ncbi.nlm.nih.gov/35985340/). Class-level reasoning, however, is not the same as measured human clearance data for this specific molecule.

Preclinical Versus Human Data

The discovery report described work spanning receptor pharmacology and animal models before the first human evaluation, and the study presented the human pharmacokinetic profile as the bridge between the two (https://pubmed.ncbi.nlm.nih.gov/35985340/). Species-specific half-life values for rodents or non-human primates are not itemised in the abstract, so this page does not assign numbers to them. Where a value cannot be sourced to a verified paper, it is omitted rather than estimated.

Why Trials Used Step-Wise Escalation

Every substantial trial in this evidence set began at a lower weekly dose and increased it in stages. The phase 2 obesity trial escalated participants toward maintenance doses of 4 mg, 8 mg or 12 mg across 48 weeks of weekly subcutaneous administration (https://pubmed.ncbi.nlm.nih.gov/37366315/), and the phase 2 diabetes trial applied a comparable escalation strategy over 36 weeks (https://pubmed.ncbi.nlm.nih.gov/37385280/). The phase 1b trial similarly used multiple ascending weekly doses over 12 weeks before larger trials proceeded (https://pubmed.ncbi.nlm.nih.gov/36354040/). Escalation is a tolerability strategy in incretin trials generally; it also means that steady-state exposure at a maintenance dose was reached only after several weeks of dosing in these protocols.

Exposure and Reported Outcomes

Pharmacokinetics matters mainly because exposure relates to effect. In the 48-week phase 2 obesity trial, researchers reported a mean weight reduction of approximately 24.2% at the highest weekly dose group by week 48 (https://pubmed.ncbi.nlm.nih.gov/37366315/). In the phase 2 type 2 diabetes trial, the study reported dose-related reductions in HbA1c and body weight over 36 weeks compared with placebo and with dulaglutide 1.5 mg (https://pubmed.ncbi.nlm.nih.gov/37385280/). A substudy of that trial reported changes in fat mass and lean mass measured by imaging (https://pubmed.ncbi.nlm.nih.gov/40609566/), and a phase 2a analysis reported reductions in liver fat content in participants with metabolic dysfunction-associated steatotic liver disease (https://pubmed.ncbi.nlm.nih.gov/38858523/). Pooled analyses of the randomised evidence reported dose-dependent weight and metabolic changes across trials (https://pubmed.ncbi.nlm.nih.gov/40291085/).

Tolerability and Adverse Events: What Studies Report

In the phase 2 obesity trial, researchers reported that the most common adverse events were gastrointestinal — nausea, diarrhoea, vomiting and constipation — and that they were generally mild to moderate and more frequent during dose escalation (https://pubmed.ncbi.nlm.nih.gov/37366315/). The phase 2 diabetes trial reported a similar gastrointestinal pattern across weekly dose groups (https://pubmed.ncbi.nlm.nih.gov/37385280/), and a systematic review and meta-analysis reported that gastrointestinal adverse events were the predominant tolerability finding across randomised trials (https://pubmed.ncbi.nlm.nih.gov/40291085/). Because these events clustered around dose increases, escalation schedules and pharmacokinetics are closely linked in the trial literature.

What the Literature Does Not Answer

• Individual exposure duration. Published half-life figures are population averages from trial pharmacokinetic analyses; the verified papers do not model individual washout timelines.
• Quantity-to-duration conversions. The trials report weekly doses in milligrams over fixed study periods, such as 48 weeks in the phase 2 obesity trial (https://pubmed.ncbi.nlm.nih.gov/37366315/); they do not describe container volumes, supply calculations or how long any quantity of material would last outside a protocol.
• Organ impairment and interactions. No dedicated renal, hepatic or drug-interaction pharmacokinetic studies appear in the verified set.
• Long-term steady-state data. Ongoing registrational trials, including the TRIUMPH programme in obesity, obstructive sleep apnoea and knee osteoarthritis, were described at the design stage (https://pubmed.ncbi.nlm.nih.gov/41090431/), and phase 3 results in type 2 diabetes have begun to appear (https://pubmed.ncbi.nlm.nih.gov/42250575/).

Retatrutide remains investigational; it is not an approved medicine, and material sold under that name outside clinical trials is not a pharmaceutical product with an approved label. Anyone with clinical questions should direct them to a licensed physician rather than to the trial literature, which describes controlled research settings only.

References

• LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept (Cell Metabolism, 2022)
• LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial (Lancet, 2022)
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (New England Journal of Medicine, 2023)
• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (Lancet, 2023)
• Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (Nature Medicine, 2024)
• Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials (Metabolism Open, 2024)
• The power of three: Retatrutide's role in modern obesity and diabetes therapy (European Journal of Pharmacology, 2024)
• Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials (Proceedings (Baylor University Medical Center), 2025)
• Retatrutide-A Game Changer in Obesity Pharmacotherapy (Biomolecules, 2025)
• Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial (Lancet Diabetes & Endocrinology, 2025)
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials (Diabetes, Obesity & Metabolism, 2026)
• Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (Lancet, 2026)